PACIRA Aktie

 

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio....

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio....

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN PACIRA BIOSCIENC. DL-,001 82P US6951271005 AB/FROM ONWARDS 08.10.2026 14:41 CET...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL PACIRA BIOSCIENC. DL-,001 82P US6951271005 BAW/UFN...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Instrument ID [9744] (82P - US6951271005) suspended...

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global......

Press release announcing the findings of a collaborative study with Caregiver Action Network about the caregiver experience....

Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027....

Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply The post Pacira partners with Molteni for Exparel commercialisation appeared first on Pharmaceutical Business review....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – ...

Slonin, Jonathan - Vorstand - Tag der Transaktion: 2026-08-17...

EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage....

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval....

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —...

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pacira (PCRX) delivered earnings and revenue surprises of +14.06% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...